| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues: | ||||||||||
Total revenues | ||||||||||
120,282 | 251,453 | 141,102 | 108,973 | 71,914 | 64,538 | 48,973 | 31,388 | 30,037 | 23,538 | 38,940 |
Operating costs and expenses: | ||||||||||
Cost of Captisol | ||||||||||
11,347 | 6,337 | 5,366 | 5,571 | 5,807 | 9,136 | 5,732 | 3,601 | 4,909 | 0 | - |
Amortization of intangibles | ||||||||||
16,864 | 15,792 | 12,120 | 10,643 | 2,375 | 2,375 | - | - | - | - | - |
Research and development | ||||||||||
55,908 | 27,863 | 26,887 | 21,221 | 11,005 | 9,747 | 9,274 | 10,790 | 10,291 | 22,067 | 39,870 |
General and administrative | ||||||||||
41,884 | 37,734 | 28,653 | 27,653 | 25,398 | 22,570 | 17,984 | 15,782 | 14,583 | 12,829 | 15,211 |
Lease exit and termination costs | ||||||||||
- | - | - | - | - | 1,084 | 560 | 1,022 | 552 | 16,894 | 15,235 |
Write-off of acquired IPR&D | ||||||||||
- | - | - | - | - | - | 480 | 0 | 2,282 | 2,754 | 442 |
Total operating costs and expenses | ||||||||||
126,003 | 87,726 | 73,026 | 65,088 | 44,585 | 44,912 | 34,030 | 31,195 | 32,617 | 54,544 | 70,758 |
Gain from sale of Promacta license | ||||||||||
812,797 | 0 | 0 | - | - | - | - | - | - | - | - |
Accretion of deferred gain on sale leaseback | ||||||||||
- | - | - | - | - | - | - | - | 1,702 | 1,702 | 21,851 |
Income from operations | ||||||||||
807,076 | 163,727 | 68,076 | 43,885 | 27,329 | 19,626 | 14,943 | 193 | -878 | -29,304 | -9,967 |
Other income (expense): | ||||||||||
Increase in contingent liabilities | ||||||||||
- | - | - | - | -5,013 | -5,135 | -3,597 | -1,650 | -1,013 | 9,142 | - |
Gain (loss) from Viking | ||||||||||
2,888 | 50,187 | -2,048 | -23,132 | -5,143 | 0 | 0 | - | - | - | - |
Interest income | ||||||||||
28,430 | 13,999 | 2,060 | 664 | - | - | - | - | - | - | 586 |
Interest expense | ||||||||||
35,745 | 48,276 | 13,460 | 12,842 | -11,802 | -4,860 | -2,077 | -2,924 | -2,297 | 382 | 270 |
Gain on deconsolidation of Viking | ||||||||||
- | - | - | - | 28,190 | 0 | 0 | - | - | - | - |
Other expense, net | ||||||||||
-6,010 | -6,307 | 2,603 | -615 | 1,768 | 1,671 | -63 | 516 | 630 | 4,377 | -221 |
Total other income (loss), net | ||||||||||
-10,437 | 9,603 | -10,845 | -35,925 | 8,000 | -8,324 | -5,737 | -4,058 | -2,680 | 13,901 | 95 |
Income (loss) before income taxes | ||||||||||
796,639 | 173,330 | 57,231 | 7,960 | 35,329 | 11,302 | 9,206 | -3,865 | -3,558 | -15,403 | -9,872 |
Income tax benefit (expense) | ||||||||||
167,337 | 30,009 | 44,675 | 10,327 | -192,115 | 410 | 374 | -1,191 | -13,270 | -2,617 | -1,535 |
Income (loss) from operations | ||||||||||
- | - | - | -2,367 | 227,444 | 10,892 | 8,832 | -2,674 | - | - | - |
Discontinued operations: | ||||||||||
Net income from continuing operations | ||||||||||
- | - | - | - | - | - | 8,832 | -2,674 | 9,712 | -12,786 | -8,337 |
Gain on sale of Oncology Product Line before income taxes | ||||||||||
- | - | - | 1,139 | 0 | 0 | - | - | - | - | - |
Income tax expense on discontinued operations | ||||||||||
- | - | - | 400 | 0 | 0 | - | 1,509 | 0 | 0 | - |
Income from discontinued operations | ||||||||||
- | - | - | 731 | 0 | 0 | 2,588 | 3,656 | - | - | - |
Income from discontinued operations | ||||||||||
- | - | - | - | - | - | - | 2,147 | 3 | 2,413 | 6,389 |
Net income (loss) including noncontrolling interests | ||||||||||
- | - | - | - | 227,444 | 10,892 | - | - | - | - | - |
Less: Net loss attributable to noncontrolling interests | ||||||||||
- | - | - | - | 2,380 | -1,132 | - | 0 | - | - | - |
Net income (loss) | ||||||||||
629,302 | 143,321 | 12,556 | -1,636 | 229,824 | 12,024 | 11,420 | -527 | 9,715 | -10,373 | -1,948 |
Earnings Per Share [Abstract] | ||||||||||
Earnings Per Share, Basic and Diluted: | ||||||||||
Income (loss) from continuing operations (USD per share) | ||||||||||
- | - | - | -0.11 | 11.61 | 0.59 | 0.43 | -0.14 | 0.49 | -0.65 | -0.44 |
Income from discontinued operations (USD per share) | ||||||||||
- | - | - | 0.04 | 0.00 | 0.00 | 0.13 | 0.11 | 0.00 | - | - |
Basic net income (loss) per share (USD per share) | ||||||||||
33.13 | 6.77 | 0.60 | -0.08 | 11.61 | 0.59 | 0.56 | -0.03 | 0.49 | - | - |
Weighted average common shares outstanding: | ||||||||||
Discontinued operations (in usd per share) | ||||||||||
- | - | - | - | - | - | - | - | - | 0.12 | 0.34 |
Basic and diluted net income per share (in usd per share) | ||||||||||
- | - | - | - | - | - | - | - | - | -0.53 | -0.10 |
Shares used in basic per share calculations (shares) | ||||||||||
18,995 | 21,160 | 21,032 | 20,831 | 19,790 | 20,419 | 20,312 | 19,853 | 19,655 | 19,613 | 18,862 |
Diluted per share amounts: | ||||||||||
Income (loss) from continuing operations (USD per share) | ||||||||||
- | - | - | -0.11 | 10.83 | 0.56 | 0.43 | -0.14 | 0.49 | - | - |
Income from discontinued operations (USD per share) | ||||||||||
- | - | - | 0.04 | 0.00 | 0.00 | 0.12 | 0.11 | 0.00 | - | - |
Diluted net income (loss) per share (USD per share) | ||||||||||
31.85 | 5.96 | 0.53 | -0.08 | 10.83 | 0.56 | 0.55 | -0.03 | 0.49 | - | - |
Shares used in diluted per share calculations (shares) | ||||||||||
19,757 | 24,067 | 23,481 | 20,831 | 21,228 | 21,433 | 20,745 | 19,853 | 19,713 | 19,613 | 18,862 |
Royalties | ||||||||||
Total revenues | ||||||||||
46,976 | 128,556 | 88,685 | 59,423 | 38,194 | 29,994 | 23,584 | 14,073 | 9,213 | 7,279 | 8,334 |
Captisol | ||||||||||
Total revenues | ||||||||||
31,489 | 29,123 | 22,070 | 22,502 | 27,662 | 28,488 | 19,072 | 9,432 | 12,123 | 0 | - |
License fees, milestones and other revenues | ||||||||||
Total revenues | ||||||||||
41,817 | 93,774 | 30,347 | 27,048 | 6,058 | 6,056 | 6,317 | 7,883 | 8,701 | 16,259 | 30,606 |